
Salts and Derivatives of Active Pharmaceutical Ingredients (API)
The salts of Active Pharmaceutical Ingredients (APIs) are compounds formed by the reaction of an acid with a base, resulting in an ionic equilibrium. These salts often improve the solubility and stability of APIs, facilitating their absorption in the body. API derivatives are chemical variants of an active ingredient that may have enhanced or modified properties to optimise therapeutic efficacy. API salts are used in the formulation of oral, injectable, and topical medications. Additionally, API derivatives can improve the pharmacokinetics of drugs, such as enabling controlled release of active substances.
At CymitQuimica, we provide API salts and derivatives with the necessary purity and quality for research and pharmaceutical formulation development.
Found 79283 products of "Salts and Derivatives of Active Pharmaceutical Ingredients (API)"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Acyclovir Related Compound G (2-{[2-(Acetylamino)-6-oxo-1,6-dihydro-9H-purin-9-yl]methoxy}ethyl acetate)
CAS:Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoiFormula:C12H15N5O5Color and Shape:White Pale Yellow PowderMolecular weight:309.10732Gatifloxacin Related Compound A (1-Cyclopropyl-6-fluoro-8-hydroxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid)
CAS:Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, nesoiFormula:C18H20FN3O4Color and Shape:Yellow SolidMolecular weight:361.14378Ticlopidine Related Compound B (5-(2-chlorobenzyl)-4-oxo-4,5,6,7-tetrahydrothieno-[3,2-c]pyridine)
CAS:<p>Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoi</p>Formula:C14H12ClNOSColor and Shape:White PowderMolecular weight:277.03281Bendamustine Related Compound A (4-{5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride)
CAS:Heterocyclic compounds with nitrogen hetero-atom(s) only, aromatic or modified aromatic, nesoiFormula:C16H23N3O4HClColor and Shape:White SolidMolecular weight:357.83Benazepril Related Compound E (3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine-1-acetic acid, monohydrochloride)
CAS:Lactams, nesoiFormula:C12H14N2O3·HClColor and Shape:White Crystalline PowderMolecular weight:270.72Gabapentin Related Compound B ((1-cyanocyclohexyl)acetic acid)
CAS:Nitrile function compounds, nesoiFormula:C9H13NO2Color and Shape:PowderMolecular weight:167.21Budesonide Related Compound E (16α,17-[butylidenebis(oxy)]-11β,21-dihydroxypregna-1,4,14-triene-3,20-dione)
CAS:<p>Adrenal cortical hormones and their derivatives nesoi</p>Formula:C25H32O6Color and Shape:PowderMolecular weight:428.21989Nicardipine Related Compound B (3-{2-[Benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate oxalate)
Compounds containing an unfused pyridine ring in the structure, nesoiFormula:C26H27N3O6·C2H2O4Color and Shape:Off-White SolidMolecular weight:567.55Nepafenac Related Compound A (2-{2-Amino-3-[hydroxy(phenyl)methyl]phenyl}acetamide)
CAS:Aromatic cyclic amides (including cyclic carbamates) and their derivatives; salts thereofFormula:C15H16N2O2Color and Shape:White SolidMolecular weight:256.31Losartan Related Compound C (2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazol-5-carbaldehyde)
CAS:Compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure nesoiFormula:C22H21ClN6OColor and Shape:PowderMolecular weight:420.14654Febuxostat Related Compound C (Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate)
CAS:<p>Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure</p>Formula:C14H12N2O3SColor and Shape:Off-White Fine PowderMolecular weight:288.05686Gatifloxacin Related Compound D (1-Cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid)
CAS:Products described in u.s. note 3 to section 6 containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structureFormula:C18H20FN3O4Color and Shape:SolidMolecular weight:361.14378Irinotecan Related Compound A ((S)-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione)
CAS:<p>Other alkaloids,natural or reproduced by synthesis, and their salts, ethers,esters&other derivatives, nesoi</p>Formula:C20H16N2O5Color and Shape:Light Yellow PowderMolecular weight:364.10592Mecamylamine Related Compound A (N,1,7,7-Tetramethylbicyclo[2.2.1]heptan-2-amine hydrochloride)
CAS:<p>Cyclanic, cyclenic or cycloterpenic mono- or polyamines, and their derivatives; salts thereof</p>Formula:C11H21N·HClColor and Shape:White PowderMolecular weight:167.1674Acyclovir Related Compound A (2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl acetate)
CAS:<p>Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoi</p>Formula:C10H13N5O4Color and Shape:White Crystalline PowderMolecular weight:267.09675Meloxicam Related Compound A (ethyl-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate- 1,1-dioxide)
CAS:Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormula:C12H13NO5SColor and Shape:White SolidMolecular weight:283.05144Temozolomide Related Compound A (4-diazo-4H-imidazole-5-carboxamide)
CAS:Compounds containing an unfused imidazole ring (whetherFormula:C4H3N5OColor and Shape:PowderMolecular weight:137.03376


